secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001193125-25-125881
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena's Phase 3 AFFIRM-AL trial for birtamimab fails; development halted; workforce reduction planned
--------------------------------------------------------------------------------

- Phase 3 AFFIRM-AL did not meet primary endpoint of all-cause mortality (HR=0.915, p=0.7680); secondary endpoints also missed.
- Birtamimab development discontinued; open-label extension stopped.
- Company to substantially reduce workforce and operating expenses; further update expected in June 2025.
- Birtamimab was generally safe and well-tolerated, consistent with prior safety profile.
- Upcoming data: PRX012 Phase 1 ASCENT (Alzheimer's) in August; partner updates from Roche, Novo Nordisk, BMS in 2025-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000119312525125881/0001193125-25-125881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000119312525125881/d891971d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-125881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer